CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) is one of 295 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare CARGO Therapeutics to related companies based on the strength of its profitability, valuation, dividends, risk, institutional ownership, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for CARGO Therapeutics and its competitors, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
CARGO Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
CARGO Therapeutics Competitors | 1707 | 5015 | 13045 | 255 | 2.59 |
CARGO Therapeutics presently has a consensus target price of $30.33, indicating a potential upside of 35.66%. As a group, “Biological products, except diagnostic” companies have a potential upside of 55.28%. Given CARGO Therapeutics’ competitors higher probable upside, analysts clearly believe CARGO Therapeutics has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
Profitability
This table compares CARGO Therapeutics and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
CARGO Therapeutics | N/A | -50.68% | -38.69% |
CARGO Therapeutics Competitors | -4,896.61% | -157.97% | -42.54% |
Valuation & Earnings
This table compares CARGO Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
CARGO Therapeutics | N/A | -$98.15 million | -0.44 |
CARGO Therapeutics Competitors | $551.79 million | -$35.20 million | -25,976.56 |
CARGO Therapeutics’ competitors have higher revenue and earnings than CARGO Therapeutics. CARGO Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
CARGO Therapeutics beats its competitors on 7 of the 12 factors compared.
About CARGO Therapeutics
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Receive News & Ratings for CARGO Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARGO Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.